Related Experiment Video
Updated: Jun 10, 2026
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line
Rong Chen1, Sherri Chubb, Tiewei Cheng
1Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center and Graduate School of Biomedical Sciences, University of Texas Houston Health Science Center, Houston, Texas 77030, USA.
Abstract:
SNS-032 is a potent inhibitor of cyclin-dependent kinases (Cdk) 2, 7, and 9 that regulate the cell cycle and transcription. Our studies in indolent primary chronic lymphocytic leukemia cells showed that SNS-032 inhibited transcription, diminished the antiapoptotic protein Mcl-1, and induced apoptosis. The present study focuses on evaluating this compound in four proliferating mantle cell lymphoma lines (Jeko-1, Granta 519, Mino, and SP-53). Consistent with its action against Cdk9 and Cdk7, SNS-032 inhibited the phosphorylation of RNA pol II in all four lines and blocked RNA synthesis. The transcripts and protein levels of short-lived proteins decreased, including cyclin D1 and Mcl-1. Cell growth was inhibited in a concentration-dependent manner in all lines. Apoptosis was induced in JeKo-1, Mino, and SP-53 cells without disrupting cell cycle distribution. However, apoptosis was limited in Granta cells; rather, there was a significant reduction of clonogenic survival. Small interfering RNA was used to specifically knock down Mcl-1 and cyclin D1 in JeKo-1 and Granta cells. Knocking down Mcl-1 induced significant apoptosis in Jeko-1 cells but not Granta cells. Reducing cyclin D1, rather than Mcl-1, was associated with loss of clonogenic survival in Granta cells. Thus, these results indicated that mantle cell lymphoma cell lines have distinct mechanisms sustaining their survival, and the mechanism of action of SNS-032 is dependent on the biological context of an individual line.
Insights
SNS-032, a cyclin-dependent kinase inhibitor, effectively reduces cell growth and induces apoptosis in most mantle cell lymphoma lines. However, its mechanism varies, impacting Mcl-1 or cyclin D1 levels differently based on the cell line's survival strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinases (CDKs) regulate cell cycle and transcription.
- SNS-032 is a CDK inhibitor with demonstrated effects in chronic lymphocytic leukemia.
- Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma.
Purpose of the Study:
- To evaluate the efficacy of SNS-032 in proliferating mantle cell lymphoma cell lines.
- To investigate the molecular mechanisms underlying SNS-032's action in MCL.
- To determine if MCL cell lines exhibit distinct survival mechanisms.
Main Methods:
- Treatment of four MCL cell lines (Jeko-1, Granta 519, Mino, SP-53) with SNS-032.
- Assessment of RNA polymerase II phosphorylation and RNA synthesis.
- Analysis of short-lived protein levels (cyclin D1, Mcl-1) and cell growth.
- Induction of apoptosis and cell cycle distribution analysis.
- Specific knockdown of Mcl-1 and cyclin D1 using small interfering RNA (siRNA).
Main Results:
- SNS-032 inhibited RNA polymerase II phosphorylation and RNA synthesis in all tested MCL lines.
- Cell growth was inhibited in a dose-dependent manner.
- Apoptosis was induced in Jeko-1, Mino, and SP-53 cells, while Granta cells showed reduced clonogenic survival.
- Mcl-1 knockdown induced apoptosis in Jeko-1 cells, whereas cyclin D1 reduction impacted clonogenic survival in Granta cells.
- Distinct survival mechanisms were observed in MCL cell lines.
Conclusions:
- SNS-032 exhibits anti-proliferative and apoptotic effects in MCL cell lines.
- The mechanism of action of SNS-032 is context-dependent, influenced by individual cell line survival strategies.
- Targeting Mcl-1 or cyclin D1 may have differential effects on MCL cell survival and proliferation.
More Related Videos
11:50Genome-Wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN
Published on: April 3, 2026
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019